MDS are associated in 10%–20% of cases with various systemic inflammation and autoimmune disorders (SIAD).1 Like MDS, CMML is associated with SIAD in approximately 30% of cases.2 Previously, we have shown that inflammatory pathways responsible for SIAD in CMML were not linked with the UBA1 mutation and could depend on its mutational profile.3 Studies regarding mutational status and survival that focus solely on CMML with SIAD manifestations are scarce and do not accurately differentiate between SIAD subtypes.2,4,5. This evidence concerns the gene UBA1 and chronic myelomonocytic leukemia.